Clinical trial

Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

NCT01982942

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-11-01

PhasePHASE2

Study timeline

Study start (unknown)2013-11-01Date precision: month

Registry last updated2020-07-28

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosis, Primary Progressiveunresolved

Multiple Sclerosis, Secondary Progressiveunresolved

Interventions

Placebo oral capsuleDRUG

Sponsors & collaborators

MediciNovalead sponsor

National Institutes of Health (NIH)collaborator

National Institute of Neurological Disorders and Stroke (NINDS)collaborator

National Multiple Sclerosis Societycollaborator

Mapped research locations

New YorkNew York, United States2 BostonMassachusetts, United States2 Los AngelesCalifornia, United States1 DallasTexas, United States1 St LouisMissouri, United States1 AtlantaGeorgia, United States1 MiamiFlorida, United States1 NashvilleTennessee, United States1 SeattleWashington, United States1 ClevelandOhio, United States1 PittsburghPennsylvania, United States1 BirminghamAlabama, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01982942 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.